Search research articles
Contact Us
Filters
Showing results (461-470 of 504) with videos related to
Page
of 51
Sort By:
British Journal of Pharmacology
|
March 25, 2010
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence
H Rollema, A Shrikhande, K M Ward, et al.
Cancer Research
|
March 5, 2009
Cancer-specific transgene expression mediated by systemic injection of nanoparticles
Edward J Chisholm, Georges Vassaux, Pilar Martin-Duque, et al.
The Lancet. Infectious Diseases
|
September 17, 2017
AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial
Ousmane A Koita, Lansana Sangaré, Haiyan D Miller, et al.
Malaria Journal
|
August 31, 2021
Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis
Fatoumata O Maiga, Mamadou Wele, Sounkou M Toure, et al.
Diabetes Care
|
June 16, 2021
Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study
Susan Sam, Sharon L Edelstein, Silva A Arslanian, et al.
Neuropharmacology
|
December 13, 2006
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
H Rollema, L K Chambers, J W Coe, et al.
Prostate Cancer and Prostatic Diseases
|
December 24, 2002
Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer
M R Feneley, H Jan, M Granowska, et al.
Molecular Pharmacology
|
December 1, 1996
Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation
A Nguyen, J C Kath, D C Hanson, et al.
Plos Clinical Trials
|
January 11, 2007
Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers
Fawaz Mzayek, Haiyan Deng, Frances J Mather, et al.
Angiogenesis
|
July 31, 2012
Contrasting effects of sunitinib within in vivo models of metastasis
Jonathan C Welti, Thomas Powles, Shane Foo, et al.
Page
of 51
Search research articles
Search
Showing results (461-470 of 504) with videos related to
Sort By:
Page
of 51
British Journal of Pharmacology
|
March 25, 2010
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence
H Rollema, A Shrikhande, K M Ward, et al.
Cancer Research
|
March 5, 2009
Cancer-specific transgene expression mediated by systemic injection of nanoparticles
Edward J Chisholm, Georges Vassaux, Pilar Martin-Duque, et al.
The Lancet. Infectious Diseases
|
September 17, 2017
AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial
Ousmane A Koita, Lansana Sangaré, Haiyan D Miller, et al.
Malaria Journal
|
August 31, 2021
Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis
Fatoumata O Maiga, Mamadou Wele, Sounkou M Toure, et al.
Diabetes Care
|
June 16, 2021
Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study
Susan Sam, Sharon L Edelstein, Silva A Arslanian, et al.
Neuropharmacology
|
December 13, 2006
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
H Rollema, L K Chambers, J W Coe, et al.
Prostate Cancer and Prostatic Diseases
|
December 24, 2002
Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer
M R Feneley, H Jan, M Granowska, et al.
Molecular Pharmacology
|
December 1, 1996
Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation
A Nguyen, J C Kath, D C Hanson, et al.
Plos Clinical Trials
|
January 11, 2007
Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers
Fawaz Mzayek, Haiyan Deng, Frances J Mather, et al.
Angiogenesis
|
July 31, 2012
Contrasting effects of sunitinib within in vivo models of metastasis
Jonathan C Welti, Thomas Powles, Shane Foo, et al.
Page
of 51